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Abstract
Tumstatin is an anti-angiogenic collagen IV a3 fragment, levels of which are reduced in the airways of asthmatics. Its
reduction may be due to the degradation by extracellular matrix (ECM) proteases. Cathepsins play a role in ECM
remodelling, with cathepsin D, H and K (CTSD, CTSH and CTSK) being associated with lung diseases. CTSD modulates the
NC1 domains of collagen molecules including tumstatin, while CTSH and CTSK are involved in ECM degradation. The role of
these cathepsins in the regulation of tumstatin in the lung has not previously been examined. We demonstrated that CTSB,
D, F, H, K, L and S mRNA was expressed in the airways. Quantification of immunohistochemistry showed that there is no
difference in the global expression of CTSD, CTSH and CTSK between asthmatics and non-asthmatics. CTSD and CTSK, but
not CTSH had the capacity to degrade tumstatin. No difference was observed in the activity of CTSD and H in
bronchoalveolar lavage fluid of asthmatic and non-asthmatics, while CTSK was undetectable. This indicates that while CTSD
possesses the potential to directly regulate tumstatin, and thus angiogenesis through this mechanism however, it is not
likely to be involved in the dysregulation of tumstatin found in asthmatic airways.
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Introduction
Asthma is a chronic inflammatory disease of the airways which
is characterized by airway hyperresponsiveness [1] and airway
remodelling [2,3]. Airway remodelling involves structural changes
including increased airway smooth muscle mass, thickening of the
basement membrane, increased angiogenesis and altered compo-
sition of the extracellular matrix (ECM) [2,3].
Angiogenesis is the formation of new blood vessels from existing
ones. In healthy individuals, this process is tightly regulated by a
balance of pro- and anti-angiogenic factors. However in asthmat-
ics, this balance is disrupted and there is an increase in both the
number and the size of blood vessels in the airway tissue [4,5].
The ECM is a complex network of macromolecules which
maintains the structural integrity of tissues. In asthmatic airways
the composition of the ECM is altered compared to non-
asthmatics, with an increased deposition of collagen I, III and
V, fibronectin, heparan sulfate proteoglycans and various other
proteins, and reduced deposition of elastin and collagen IV
(COL4) [6,7]. COL4 is a major component of the ECM which has
an important role in regulating endothelial cell proliferation and
other behaviours. The formation and survival of blood vessels is
connected with collagen synthesis and deposition in the basement
membrane [8], particularly inhibition of collagen metabolism
which has anti-angiogenic effects [9].
Six distinct isoforms of COL4 a-chains have been identified
(a1–6). The COL4 a-chains have a basic domain configuration
consisting of the N-terminal 7S domain, the collagenous domain
and the C-terminal globular non-collagenous domain 1 (NC1)
[10]. Recently it has been acknowledged that the ECM is a
reservoir for endogenous growth factors. In the body, endogenous
proteases such as matrix metalloproteinases (MMPs) and their
inhibitors tissue inhibitor metalloproteinase (TIMPs) are involved
in routine ECM turnover for the maintenance of normal tissue
homeostasis. Degradation of COL4 a-chains by MMPs leads to
the release of the NC1 domains which can function as active
peptides. One example is the NC1 domain of the COL4a3 chain,
tumstatin, a potent anti-angiogenic factor [2,8,11,12,13].
Tumstatin expression was found to be significantly reduced in
human asthmatic compared to non-asthmatic airway tissue
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sections [2]. As COL4a3 is deposited in the ECM as a component
of a heterotrimer of a3a4a5 [14] the presence of the other NC1
domains of the COL4 a-chains in the asthmatic airway tissue [2],
indicate that the NC1 domain of COL4a3 was likely to have been
degraded following deposition into the ECM by the action of
endogenous proteases.
One such family of protease is the cathepsins, papain like
cysteine and aspartic proteases capable of degrading ECM
components with unique collagenolytic activity. They can function
both intra- and extracellularly and also participate in wound
healing and tumour cell invasion [15,16]. Cathepsins are
expressed in most tissues throughout the body. Cathepsin D
(CTSD), H (CTSH) and K (CTSK) are found in the lung and are
associated with inflammatory lung diseases [17], whilst other
members of the cathepsin family such as cathepsin B (CTSB), F
(CTSF), L (CTSL) and S (CTSS) [18] have the potential to
participate in ECM remodelling. The expression and activity of
these proteases in asthma is unknown.
CTSB, F, H, K, L and S are cysteine proteases which are
predominantly expressed by lung granulomatous lesions, bronchial
epithelium [19], metastatic lung tumors [20,21] and inflammatory
cells [22,23,24,25,26,27]. CTSK is the most potent mammalian
elastase reported to date [16,28]. CTSD is an aspartic protease
that digests expired and denatured proteins or abnormal proteins
into large fragments which are more accessible by other proteases.
It cleaves proteoglycan polypeptides and collagen [29].
A number of cathepsins have previously been identified as
having a role in airway diseases. Expression of CTSD is increased
in cystic fibrosis [30], and has a role in airway remodelling during
fibrogenesis in pulmonary fibrosis [31]. CTSH is upregulated in
asthmatic serum [32] and it is increased in the parenchyma of
smoking but not non-smoking lung cancer patients [33]. CTSK
elicits a protective role during lung matrix homeostasis under
physiological and pathological conditions [16,34]. In addition,
CTSK is overexpressed in lymphangioleiomyomatosis (LAM) cells
and related renal angiolipomas [17]. Whilst it has yet to be
reported in human studies, CTSS is elevated in murine models of
allergic asthma and CTSS inhibition is prophylactic to ameliorate
airway inflammation [35].
Given the potential of cathepsins to degrade the ECM, and
COL4 in particular, the aim of this study was to investigate the




To investigate the presence of CTSB, D, F, H, K, L and S in
human airways, reverse transcriptase-PCR was performed on cells
isolated from human lungs to identify mRNA expression.
Expression of all cathepsin mRNA was confirmed in primary
human airway smooth muscle (ASM), airway epithelium and lung
fibroblasts (Figure 1). Two splice variants were found to be
expressed by CTSL.
Cathepsin protein production and release by structural
cells. To investigate the release of cathepsins by structural cells,
western immunoblots were conducted on total cell lysates
(intracellular cathepsin) and supernatants (extracellular cathepsin)
on ASM and lung fibroblasts. Intracellular CTSD, B, K and S
presence was identified in all cell types (Figure 2), but no release
detected (data not shown). CTSH, L and F were not examined by
western blot as the tools for this were not available.
Detection of Cathepsins in Airway Tissue
Immunohistochemistry (IHC) was then performed on paraffin
embedded formalin fixed airway tissue sections to identify protein
production of CTSD, CTSH and CTSK. IHC showed that the
three cathepsins were expressed in the airways; CTSH and CTSK
were ubiquitously expressed, while CTSD appeared to have high
expression confined to the epithelial layer with underlying low
expression throughout the tissue (Figure 3). Densitometric analysis
Figure 1. CTSB, D, F, H, K, L and S mRNA expression quantified
by reverse transcriptase PCR. ASM (n= 3), lung fibroblast (n = 3) and
airway epithelial (n = 3). Predicted band size indicated by (2).
Abbreviations CTSB= cathepsin B, CTSD= cathepsin D, CTSF = cathepsin
F, CTSH = cathepsin H, CTSK = cathepsin K, CTSL = cathepsin L,
CTSS = cathepsin S and ASM=airway smooth muscle.
doi:10.1371/journal.pone.0057245.g001
Figure 2. CTSB, D, K and S protein expression quantified by
western immunoblot. A representative image of GAPD for each
membrane is shown. ASM (n= 3), lung fibroblasts (n = 3) and airway
epithelial (n = 3). Abbreviations CTSB= cathepsin B, CTSD= cathepsin D,
CTSK= cathepsin K, CTSS= cathepsin S, GAPD=glyceraldehyde-3-phos-
phate dehydrogenase and ASM= airway smooth muscle.
doi:10.1371/journal.pone.0057245.g002
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comparing asthmatic and non-diseased control sections showed no
difference in the staining of CTSD, CTSH and CTSK (Figure 4a,
b, c). As CTSD expression was localised to the epithelial layer, to
avoid bias due to epithelial layer variability in each tissue section
densitometry specifically targeting the epithelial layer was
performed and the results normalized to the area of epithelial
layer analyzed, which detected no difference between asthmatic
and non-asthmatics (Figure 4d).
Recombinant tumstatin digestion by cathepsins. A
digestion assay was conducted to evaluate the ability of CTSD,
CTSH and CTSK to degrade recombinant human tumstatin
using purified enzymes at close to physiological concentrations
[36,37]. The physiological concentration of CTSK in human
serum is at 3.1–9.4 pM [38,39] however the levels of CTSK in the
lung were unknown; as such the concentration used for CTSH was
used as a guide. These concentrations may not represent the
localized extracellular matrix concentrations in tissue where much
higher concentrations can be achieved locally following release
from lysosomes. CTSD and CTSK digestion of recombinant
tumstatin occurred significantly at 4 and 2 hours, respectively
(Figure 5), while no digestion was observed with CTSH (data not
shown).
Cathepsin activity in bronchoalveolar lavage fluid
(BALF). There was no difference between CTSD or CTSH
activity measured between asthmatic and non-asthmatic BALF
(Figure 6) while there was no measureable CTSK activity in
asthmatic and non-asthmatic BALF (data not shown).
Discussion
In this study we have shown, for the first time, that airway
structural cells express CTSB, D, F, H, K, L and S mRNA and
protein, except for CTSH, F and L for which the protein was not
examined. CTSD, H and K were also detected in airway tissues
from people with and without asthma. Purified CTSD and K, but
not H, were able to digest recombinant tumstatin, however there
were no differences in the activity of CTSD or CTSH in BALF
from people with and without asthma.
Quantification of the immunohistochemistry results showed that
there were no differences in the global expression of CTSD,
CTSH and CTSK between asthmatics and non-asthmatics. Due
to a potential confounder caused by epithelial shedding which is a
process that occurs in asthmatic airways, analysis of CTSD
immunostaining was repeated to analyze specifically the differ-
ences on the epithelial layer. The results showed that there was no
significant difference between the two patient groups. However,
the immunostaining showed both intra- and extracellular expres-
sion of the enzymes and not the secreted enzymes which would act
on the ECM and thus tumstatin. The proteolytic activity of
cathepsins is also regulated by endogenous protease inhibitors such
as cystatins and while no difference was detected in the protein
expression there may still be differences in the proteolytic activity.
The potential of CTSD, CTSH and CTSK to degrade
tumstatin was investigated which revealed that CTSD and CTSK
but not CTSH have the ability to degrade tumstatin. CTSK
Figure 3. Representative images (20x magnification) of airway sections stained for cathepsins. Immunostaining of cathepsins and
corresponding isotype controls for cathepsins D (A–D), H (E–H) and K (I–L) from non-diseased and asthmatic sections. Specific staining was detected
using a chemical chromophore DAB (brown) and cell nucleus was counterstained with haematoxylin (blue). Abbreviations DAB= 3,39-
diaminobenzidine.
doi:10.1371/journal.pone.0057245.g003
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activity was not detectable in the BALF and it is likely that this is
caused by auto-degradation of CTSK enzyme during storage [40].
However there was no difference observed in the activity of CTSD
in BALF of asthmatic and non-asthmatics. This indicates that
while CTSD possess the potential to directly regulate tumstatin,
and thus angiogenesis through this mechanism, it is not likely to be
involved in the dysregulation of tumstatin found in asthmatic
airways. However CTSD may indirectly affect tumstatin regula-
tion through the ability to activate or inactivate other proteases
and as such the CTSD in the asthmatic airway could lead to a net
increase in proteolytic activity. One of the indirect mechanisms of
tumstatin regulation by CTSD is the conversion of procathepsin B
into cathepsin B (CTSB), an important angiogenesis modulator
which regulates vascular endothelial growth factor activity in
endothelial cells and digests COL4 to release tumstatin [28]. The
presence of CTSB mRNA and protein in the airway structural
cells examined in this study indicate that this potential mechanism
of tumstatin degradation is worth future investigation. There are
many other potential proteases, with CTSB, F, L and S identified
in this study being candidates, which may be implicated in the
dysregulation of tumstatin in asthmatic airways.
Experimental Procedures
Human Tissues
Isolated human airway tissue was obtained from explanted and
resected lungs and post mortem organ donors with ethical
approval from The University of Sydney and participating
hospitals (Concord Repatriation General Hospital, Sydney South
West Area Health Service and Royal Prince Alfred Hospital) for
sample collection. All patients provided written informed consent
or in the case of post mortem samples consent was obtained from
the next of kin. The samples used as non-diseased controls were
from healthy organ donors whose lungs were deemed unfit for use
in a transplant procedure. Further information on the patients can
be found in Table S1.
Human Bronchoalveolar Lavage Fluid
BALF samples were collected from asthmatic volunteers in a
previous study [41] along with non-asthmatic volunteers. The
samples were collected according to the protocol described
previously [41]. Briefly, specimens were collected via normal
saline lavage of the segmental airways and alveolar spaces
(bronchoalveolar lavage). To remove mucus and cells, the BALF
was filtered through sterile gauze and centrifuged at 580 g for
Figure 4. Cathepsin D, H and K expression in non-diseased and asthmatic tissue. Area of cathepsin D (A, ND=15 and A= 5), cathepsin H (B,
ND= 13 and A= 5), cathepsin K (C, ND=15 and A= 6) and epithelial specific cathepsin D (D, ND= 12 and A= 5) immunostaining in non-diseased and
asthmatic sections were quantified using computerized image analysis. Data are expressed as mean 6 standard error of the mean. Statistical analysis
used was student’s t-test. Abbreviations A =Asthmatic, ND=Non-Diseased and ns = no significance.
doi:10.1371/journal.pone.0057245.g004
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5 min. These samples were stored at 280uC for future investiga-
tion. Further details on patient demographics can be found in
Table S1.
Immunohistochemical Sample Preparation
Airway tissues were fixed in 4% phosphate-buffered formalin
(pH 7.2) and embedded in paraffin at the Histopathology
Laboratory at The University of Sydney and archived. Sections
of 3 mm thickness were cut using a Shandon Finesse 325 (Thermo
Scientific, Waltham, MA) microtome in the Histopathology
Laboratory and mounted on Superfrost Plus microscope slides
(Lomb Scientific, Taren Point, AUS) to be used for immunohis-
tochemical analysis.
Immunohistochemistry
Briefly, sections were de-paraffinized and subjected to appro-
priate antigen retrieval for antibody staining (details in Table S2).
Sections were then treated to minimize non-specific background
staining and incubated with primary antibodies, goat anti-human
CTSD (R&D Systems, Minneapolis, USA) [0.05 mg/mL], poly-
clonal mouse anti-human CTSH (Abnova, Taipei, Taiwan)
[0.625 mg/mL] and CTSK (Abcam, Cambridge, UK) [1 mg/mL].
Tissue staining was then visualized with substrate chromogen,
liquid 3,39-diaminobenzidine (DAB) (DakoCytomation, Glostrup,
CA). Images were then taken and immunostaining was quantified
using Image Pro Plus version 7 Software (MediaCybernetics,
Discovery Way, Acton, MA) [42,43]. Further details can be found
in Appendix S1.
Tissue Isolation and Culture
Isolation and culture of ASM and lung fibroblasts was carried
out according to the methods described previously [44,45].
The bronchial epithelial cells from were grown separately in
Ham’s F-12 (Invitrogen) with the following growth supplements:
epidermal growth factor (EGF) 0.5 ng/ml, bovine pituitary extract
50 mg/ml, hydrocortisone 0.5 mg/ml, epinephrine 0.5 mg/ml,
transferrin 10 mg/ml, insulin 5 mg/ml, retinoic acid 0.1 ng/ml,
triiodothyronine 6.5 ng/ml (Sigma, St. Louis, MO), 1% antibiotics
(Invitrogen). Ham’s F-12 (Invitrogen) with added growth factors
was used for maintaining and expanding the cells. 0.03% trypsin
with 0.3 mM EDTA (GIBCO, Grand Island, NY) was used for
dissociation of the cells from culture flasks or plates.
Figure 5. Tumstation digestion by cathepsins. Digestion assay
was performed using recombinant human tumstatin (0.1 mg/ml) and
cathepsin D (0.028 mM) 0, 2, 4, 8, 12 and 24 hours (n = 3) or cathepsin K
(1.88 mM) 0, 2 and 8 hours (n = 3), visualized by western immunoblot
and quantified by densitometry. Statistical analysis used was one-way
ANOVA. Data are expressed as mean 6 standard error of the mean.
Abbreviations ns = no significance, * = p,0.05 and ** = p,0.01.
doi:10.1371/journal.pone.0057245.g005
Figure 6. Cathepsin D and H activity assay of BALF. Cathepsin D
(A) and cathepsin H (B) activity assay graphs comparing asthmatic
(n = 6) and non-asthmatic (n = 8) BALF samples after 2 hours of
incubation in reaction buffer. Statistical analysis used was student’s t-
test. Data are expressed as mean 6 standard error of the mean.
Abbreviations ns = no significance and BALF=bronchoalveolar lavage
fluid.
doi:10.1371/journal.pone.0057245.g006
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Lung Fibroblast ASM and Epithelial Cell Culture
Culture of ASM and lung fibroblasts was carried out according
to the method described previously [44]. Briefly both ASM and
lung fibroblast cells were grown to passage 3–6 in growth media.
Cells were plated up in 6 well plate at density 16104 cell/cm2.
Cells were then left for 3 days and media was changed to quiescing
media DMEM (Invitrogen) supplemented with 0.1% bovine serum
albumin (BSA) (Sigma Aldrich, St Louis, MO, USA), and 1%
antibiotics (Invitrogen). Protein, mRNA and supernatant samples
were collected after 24 hours and stored at 280uC.
Culture of bronchial epithelial cells was carried out according to
the method described previously [46]. Bronchial epithelial cells
were detached and plated in bronchial epithelial growth medium
bronchial epithelial cell growth medium (BEGM; Cambrex Bio
Science, Walkersville, MD) and grown on 12 well cell culture
plates (BD Biosciences). Once cells reached confluence (3 days),
medium was changed to quiescing medium, bronchial epithelial
basal medium (BEBM). Supernatants, cellular protein and RNA
lysate were collected at 24 hours and stored at 280uC.
mRNA Extraction and Conversion
mRNA was extracted using the NucleoSpinH RNA II kit,
according to manufacturer’s instructions (Macherey Nagel, Duren,
Germany). Quality and quantity of mRNA was determined using
a Nanodrop 1000 (NanoDrop Technologies, Inc. Wilmington,
DE, USA). 200 ng of mRNA was converted to cDNA with the
MMLV reverse transcriptase (Invitrogen) according to the
manufacturer’s instructions. Samples were stored at 220uC before
use.
Reverse Transcriptase Polymerase Chain Reaction (RT-
PCR)
Primers were designed spaning exon-exon junctions (Gene-
works, SA, AUS). RT-PCR reactions contained 5 mM forward
primer and reverse primer; 0.2 mM of each dGTP, dCTP, dATP
and dTTP; 2 mM MgCl2; 106NH4 buffer (Bioline, London, UK);
2.5 units BIOTAQ DNA polymerase (Bioline) and 2 ml cDNA.
Total reaction volume was made up to 25 ml. PCR amplifications
were conducted on an Eppendorf gradient PCR machine
(Eppendorf, Hamburg, Germany) with conditions:295uC for
2 min, (95uC for 1 min 55–60uC for 1 min and 72uC for
1 min)625–35 cycles (Table S3).
Western Immunoblot
Protein lysates and supernatants were run on 10% polyacryl-
amide gels and transferred to polyvinylidene difluoride mem-
branes (Millipore) and block for 1 hour in 5% BSA. The
membranes were washed then incubated overnight with primary
antibody (rabbit anti-human COL4a3 Pro-1426 1:20000 (Assay-
biotech, California, USA), mouse anti-human CTSB 1:400
(Abcam), goat anti-human CTSD 1:500 (R&D), rabbit anti-
human CTSK 1:1000 (Abcam), goat anti-human CTSS 1:200
(Abcam) or mouse anti-human glyceraldehydes-3-phosphate
dehydrogenase (GAPD) 1:20000 (Millipore) in 1% BSA. The
membranes were washed then incubated for 1 hour with
appropriate secondary antibody (Dako) in 1% BSA. Detection
was performed using Immobilon Western (Millipore) and bands
were analyzed using a Kodak imaging system and software.
Membranes were stripped and reprobed for as a loading control
GAPD or other cathepsins.
Cloning of Tumstatin and Expression in Escherichia coli
(E.coli)
Primers were designed for the N and C terminal regions of COL
IV a 3 NC1 (derived from Uniprot, code Q01955; ,28 kDa;
225aa) according to [47]. To obtain COL IV a 3 mRNA,
endothelilal cells were extracted from pulmonary blood vessel
dissections of donor lungs as described earlier [2]. These cells were
grown to confluence and total RNA was extracted using
NucleoSpin RNA II kit according to manufacturer’s instructions
(Macherey Nagel, Du¨ren, Germany). Total RNA was then
transcribed into cDNA using hexameric primers (New England
Biolabs, Ipswich, MA, USA) and Superscript III (Invitrogen).
cDNA then was amplified with the following primers: Forward: 39-
GGAATTCCATATGCCGGGTTTGAAAGGAAAACGTC-59,
39-CGGGATCCTCAGTGTCTTTTCTTCATGCA-59 (reverse)
with restriction sites for NdeI (forward) and BamHI (reverse): PCR
amplification was undertaken for 35 cycles with the following
conditions denaturation at 95uC for 15 sec, annealing at 60uC for
30 sec and elongation at 72uC for 60 sec. The amplicon (750 bp)
was eluted from a 1.5% Agarose gel (Amresco, Cochran Solon,
OH, USA) using a QIAEX II gel extraction kit (Qiagen,
Doncaster, VIC, Australia) and cloned into pcDNA5/FRT/TO-
TOPO (Invitrogen) according to manufacturer’s recommenda-
tions. The vector was then transformed into TOP10 E.coli
(Invitrogen) and streaked on agar plates with ampicillin (100 mg/
mL) (Sigma, St. Louis, MO, USA). Colonies were picked,
expanded and the inserts within the isolated plasmids were subject
to sequencing (Supamac, Sydney, Australia). Positive clones were
selected and archived for later use. Tumstatin was then subcloned
into pET15b (via BamHI and NdeI) and transformed into BL21
(DE3) (Bioline, Sydney, NSW, Australia) for expression. E.coli
were grown overnight, and then expansion cultures were started
with an innoculum of OD 0.1 and grown until they reached OD
0.5. Expression was then induced with 500 mM of isopropyl 1-thio-
b-D-galactopyranoside (IPTG, Sigma, St. Louis, MO, USA) for
4 h and cells were pelleted thereafter at 4uC at 40006g for
40 min. Pellets were collected and then resuspended in buffer A
(50 mM Tris–HCl, 5 mM EDTA, pH 7.5). Cells were then
sonicated on ice for 50 cycles (4s at 60% of max. amplitude and 6 s
pause). The suspension was pelleted at 15 0006g for 20 min
before washing with solubilisation buffer 1 (1% Triton X-100 and
3 M urea). The supernatant (150006g, 20 min) was removed and
inclusion bodies were incubated with solubilisation buffer 2 (6 M
guanidine hydrochloride, 0.1 M NaH2PO3, and 10 mM Tris–
HCl, pH 5.5) for 2 h at RT. Insoluble debris was spun down and
the lysate was either purified via a Nickel-sepharose column
(AmershamPharmacia, GE Healthcare, Rydalmere NSW, Aus-
tralia) or directly processed by dilution and dialysis. For dilution
and dialysis, 10 mM dithiothreitol (DTT) was added to the
inclusion body lysis solution (IBS) and incubated for 15 min at RT.
IBS was then diluted and concentrated twice as follows: Dilution
with MilliQ water and centrifugation at 1000 rpm for 45 min at
4uC in ultra filtration units (Amicon Ultra15, 10 kDa, (Millipore).
Final concentrate was dialysed against MilliQ water (1:4000).
Purified protein was analysed on polyacrylamide gel electropho-
resis (PAGE) for purity (Coomassie Blue staining) and frozen at
280uC for later use. The protein concentration was measured by
UV (280 nm, NanoDrop, Wilmington, DE, USA) and Bicincho-
ninic Acid Assay (Sigma).
Enzyme Digestion Assay
Enzyme digestion assays were performed on recombinant
human tumstatin using purified CTSD (Sigma), CTSH (Enzo
Life Sciences, Farmingdale, USA) and pro-cathepsin K (Enzo Life
The Expression Cathepsins in Asthmatic Airways
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Sciences). Pro-cathepsin K was activated according to manufac-
turer’s instructions by adding 32.5 mM sodium acetate pH 3.5 to
pro-cathepsin K at 1:6 ratio and incubation at room temperature
for 3 hours. Cathepsins were used to digest 0.1 mg/mL tumstatin
at concentrations within the active range previously identified in
the literature. CTSD digestion was performed at 27.5 nM CTSD
in 200 mM sodium citrate at pH 5.0 [48]. CTSH digestion was
performed at 1 mM CTSH in 0.05 mM sodium acetate, 10 mM
ethylenediaminetetraacetic acid (EDTA) and 1 mM L-cysteine
HCL Monohydrate at pH 5.5 [49]. CTSK digestion was
performed at 1.83 mM CTSK in 50 mM sodium acetate, 2 mM
DTT, 2 mM EDTA acid and 350 mM sodium chloride at pH 7.0
[50]. Digestion experiments were performed over a time course of
0, 2, 4, 8, 12 and 24 hours. The reactions were terminated by the
addition of loading dye 0.312 M tris-HCl, 50% glycerol, 10%
SDS, 0.5 M DTT and 0.05% bromophenol blue at pH 6.8 to 1:5
ratio and heat inactivation for 10 mins at 95uC. Samples were
visualised by western immunoblot using an anti-tumstatin
antibody (Assay Biotechnology, Sunnyvale USA) [40 ng/mL].
Cathepsin D, H and K Activity Assay
Activity of the enzymes was analysed using fluorometric activity
assay kits for cathepsin D (Abcam), H (Abcam) and K (Abcam).
Serum and BALF samples were diluted 1:1 with lysis buffer (triton
X-100 1% (w/v)) and loaded onto a 96-well black with clear
bottom plate (BD Biosciences). Then an equal volume of
mastermix containing reaction buffer and fluorometric substrate
was added into each assay well. Positive control proteins cathepsin
D (Sigma-Aldrich) [500 ng/well], H (Enzo Life Sciences) and K
(Enzo Life Sciences) were added and a negative control of lysis
buffer was also included. All assay samples were measured in
duplicate.
Supporting Information
Table S1 Patient demographics of the individual pa-
tients within the sample group used for immunohisto-
chemical analysis and enzyme activity assays.
(DOCX)
Table S2 Antibody dependent treatment of airway
sections.
(DOCX)
Table S3 PCR conditions for cathepsin primers.
(DOCX)
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